Fatty Liver Disease - Pipeline Review, H1 2012

Global Markets Direct, February 2012, Pages: 78

Fatty Liver Disease – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Fatty Liver Disease - Pipeline Review, H1 2012', provides an overview of the Fatty Liver Disease therapeutic pipeline. This report provides information on the therapeutic development for Fatty Liver Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fatty Liver Disease. 'Fatty Liver Disease - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Fatty Liver Disease.
- A review of the Fatty Liver Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Fatty Liver Disease pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Fatty Liver Disease.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Fatty Liver Disease pipeline depth and focus of Fatty Liver Disease therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Fatty Liver Disease Therapeutic Products under Development, Key Players in Fatty Liver Disease Therapeutics, Fatty Liver Disease Pipeline Overview, Fatty Liver Disease Pipeline, Fatty Liver Disease Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Fatty Liver Disease Overview
Therapeutics Development
An Overview of Pipeline Products for Fatty Liver Disease
Fatty Liver Disease Therapeutics under Development by Companies
Fatty Liver Disease Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Fatty Liver Disease Therapeutics – Products under Development by Companies
Fatty Liver Disease Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Fatty Liver Disease Therapeutics Development
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
GW Pharmaceuticals plc
Phynova Group Ltd
7TM Pharma A/S
Phenex Pharmaceuticals AG
Obio Pharmaceutical Holdings Limited.
Jenken Biosciences, Inc
Galmed International Ltd.
Connexios Life Sciences Pvt. Ltd.
Fatty Liver Disease – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
MK-4074 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TM38837 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PYN22 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Legalon - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aramchol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JKB-121 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AK20 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Byetta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RO5093151 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ezetimibe - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pitavastatin Calcium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Byetta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Metformin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Omacor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Omegaven - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pioglitazone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Berberine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cannabidiol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Spironolactone + Vitamin E - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GR-MD-02 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oltipraz - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Px-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CNX-FC010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Liraglutide + Metformin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fatty Liver Disease Therapeutics – Drug Profile Updates
Fatty Liver Disease Therapeutics – Discontinued Products
Fatty Liver Disease Therapeutics - Dormant Products
Fatty Liver Disease – Product Development Milestones
Featured News & Press Releases
Feb 08, 2012: GENFIT Announces Conclusive Results Of Regulatory Toxicology Studies With GFT505
Feb 03, 2012: GENFIT's GFT505-210-6 Phase II Clinical Study Reaches All Primary And Secondary Efficacy Objectives
Dec 19, 2011: GENFIT To Participate At Two International Conferences In San Francisco
Dec 16, 2011: Galectin Therapeutics Presents Preclinical Data On Treatment Of Fatty Liver Disease And Fibrosis At EASL
Nov 24, 2011: GENFIT Announces GFT505 Reverses Established NAFLD/NASH And Blocks Pro-Fibrotic Mechanisms
Oct 24, 2011: GENFIT Announces Implementation Of Two Groups Of Experts Dedicated To Future Development Of GFT505 In NAFLD/NASH
Oct 06, 2011: Metabolic Solutions Development Company Receives $1.1m NIH Grant To Further Investigate MSDC-0602 For Treatment Of Fatty Liver Disease
Sep 12, 2011: GENFIT Announces Preclinical Results Supporting Development Of GFT505 For Treatment Of NAFLD/NASH
Oct 14, 2010: Galmed Initiates Phase II Clinical Trial Of Aramchol For Treatment Of Fatty Liver Disease
Sep 21, 2008: Galmed Medical Research Initiates Its Phase I study Of Aramchol, Its Drug Candidate For Fatty Liver Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Fatty Liver Disease, H1 2012
Products under Development for Fatty Liver Disease – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
F. Hoffmann-La Roche Ltd., H1 2012
Merck & Co., Inc., H1 2012
GW Pharmaceuticals plc, H1 2012
Phynova Group Ltd, H1 2012
7TM Pharma A/S, H1 2012
Phenex Pharmaceuticals AG, H1 2012
Obio Pharmaceutical Holdings Limited., H1 2012
Jenken Biosciences, Inc, H1 2012
Galmed International Ltd., H1 2012
Connexios Life Sciences Pvt. Ltd., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Fatty Liver Disease Therapeutics – Drug Profile Updates
Fatty Liver Disease Therapeutics – Discontinued Products
Fatty Liver Disease Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Fatty Liver Disease, H1 2012
Products under Development for Fatty Liver Disease – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Liver Transplantation – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Pandemic Influenza – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Brain Tumor – Pipeline Review, H1 2013
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Premature Ejaculation – Pipeline Review, H1 2013
• Skin And Skin Structure Infections (SSSI) – Pipeline Review, H1 2013